A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

• Status: TERMINATED
• Trial end date: 2025-03-31

Summary

The goal of the study is to learn whether Niraparib or Platinum-Taxane Doublet chemotherapy is better in treating participants with Homologous Recombination Deficient (HRd) Stage III/IV Ovarian Cancer (OC). This study is a sub-study of the Master protocol -OPAL (NCT03574779)

• Phase: PHASE2

Details

• Lead Sponsor: Tesaro, Inc.
• Treatments: Carboplatin; niraparib; Paclitaxel